Netherlands· NL-e64a2de84dd9
Aspaveli 1080 mg oplossing voor infusie
A pegcetacoplan product containing pegcetacoplan, registered in Netherlands by Apellis Ireland Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Pegcetacoplan is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AJ03 (pegcetacoplan), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Pegcetacoplan · ATC L04AJ03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- PEGCETACOPLAN
- Manufacturer
- Apellis Ireland Limited
- Country
- Netherlands (NL)
- ATC code
- L04AJ03
- ATC class
- Pegcetacoplan
- Defined daily dose
- 0.3 g, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1595
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pegcetacoplan in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceASPAVELI 1080 mg, solution pour perfusionSWEDISH ORPHAN BIOVITRUM (SUEDE)
- United StatesEmpaveliApellis Pharmaceuticals, Inc.
- CzechiaASPAVELISwedish Orphan Biovitrum AB (publ), Stockholm
- SwitzerlandAspaveli
- FinlandASPAVELISwedish Orphan Biovitrum AB (publ)
- BelgiumAspaveli 1080 mgSwedish Orphan Biovitrum (Publ)
- IrelandASPAVELI 1 080 mg solution for infusionApellis Ireland Limited
- IcelandASPAVELI*Swedish Orphan Biovitrum AB (publ)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Aspaveli
- Liechtenstein · Aspaveli
- Norway · Aspaveli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e2e7da84-c049-4647-98ea-69e2287b5898 GET /v1/drugs/e2e7da84-c049-4647-98ea-69e2287b5898?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor infusie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/aspaveli-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Pegcetacoplan",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp127332",
"excipients": [
"AZIJNZUUR (E 260), GECONCENTREERD",
"NATRIUMACETAAT 3-WATER (E 262)",
"NATRIUMHYDROXIDE (E 524)",
"SORBITOL (E 420)",
"WATER VOOR INJECTIE"
],
"substances": [
"PEGCETACOPLAN"
],
"leaflet_url": null,
"authorised_at": "2021/12/13",
"procedure_number": "EMEA/H/C/005553",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1595",
"additional_monitoring": "N"
}See everything about pegcetacoplan.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.